anti-GPRC5D CAR-T / Guangzhou Bio-gene Technology - LARVOL DELTA

Safety and Efficacy of GPRC5D CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients (ASH 2023) - P1/2 | "Lymphodepletion with fludarabine and cyclophosphamide was performed before administering 3E6, 6E6, or 1E7/kg anti-GPRC5D CAR T cells. In conclusion, GPRC5D CAR T-cell therapy demonstrated promising clinical efficacy and tolerable safety in patients with R/R MM. For those who relapsed after anti-BCMA CAR T-cell therapy, GPRC5D CAR T-cell therapy offered an effective option (NCT05739188).""

CAR T-Cell Therapy • Clinical • Anemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

CAR T-Cell Therapy • New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology